Adicet Bio, Inc. (ACET) annual cash flow statement — 18-year operating, investing & financing history
Adicet Bio, Inc. (ACET) cash flow statement — 18-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 | Jun'10 | Jun'09 | Jun'08 |
|---|
| Cash from Operations | -80.14M | -95.25M | -92.38M | -93.72M | -44.77M | -51.05M | -41.55M | -27.88M | -18.18M | -11.55M | 8.34M | 25.06M | 25.48M | 23.73M | 13.27M | 14.04M | -15.5M | 22.51M | 15.42M |
| Operating CF Margin % | - | - | - | - | -179.13% | -524.69% | -232.1% | -2802.21% | -222.22% | -2.07% | 1.53% | 4.91% | 5.1% | 4.75% | 2.99% | 3.4% | -4.47% | 6.98% | 4.29% |
| Operating CF Growth % | 73.86% | -3.1% | 1.43% | -109.35% | 12.31% | -22.86% | -49.03% | -53.37% | -57.36% | -238.48% | -66.7% | -1.65% | 7.35% | 78.85% | -5.48% | 190.57% | -168.85% | 46% | - |
| Net Income | -91M | -116.8M | -117.12M | -142.66M | -69.79M | -62M | -36.68M | -28.14M | -9.3M | -33.78M | 33.48M | 29M | 22.33M | 22.33M | 16.98M | 8.97M | 6.58M | 8.63M | 13.47M |
| Depreciation & Amortization | 3.13M | 6.38M | 6.47M | 6.1M | 2.67M | 1.54M | 1.23M | 1.24M | 80K | 5K | 11.85M | 8.09M | 6.94M | 6.94M | 6.94M | 5.5M | 2.8M | 1.87M | 2.38M |
| Stock-Based Compensation | 9.9M | 14.27M | 22.23M | 20.26M | 17.13M | 12.51M | 5.26M | 1.18M | 2.48M | 470K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 1.23M | 3.2M | 0 | 0 | 18K | 1.87M | 3.08M | 2.65M | 2.65M | 1.78M | -675K | -796K | 191K | -121.46M |
| Other Non-Cash Items | -4.81M | -564K | 1.57M | 22.33M | 2.49M | 1.72M | -1.04M | -2.5M | -3.39M | 16.57M | -70.88M | -47.71M | -18.3M | -12.88M | -8.1M | 3.17M | -21.05M | -134.44M | -1.72M |
| Working Capital Changes | 2.64M | 1.47M | -5.53M | 252K | 2.74M | -6.06M | -13.52M | 341K | -8.05M | 4.26M | 27.48M | 29.44M | 10.06M | 2.9M | -5.5M | -3.79M | -4.08M | 144.71M | 121.46M |
| Change in Receivables | 0 | 0 | 0 | 0 | 185K | -30K | 0 | 0 | 0 | -6.15M | -44.18M | -19.4M | -14.98M | -14.98M | 5.71M | 1.92M | -30.85M | 18.45M | -7.33M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 2.01M | 0 | 0 | 0 | -2.49M | -229K | -7.76M | 1.63M | 1.63M | -9.93M | 2.22M | 859K | 14.77M | 0 |
| Change in Payables | -1.72M | 1.03M | 1.11M | -1.68M | 1.71M | 1.14M | -814K | 527K | -282K | 1.39M | 8.13M | 5.22M | -3.23M | -3.23M | -978K | 2.47M | 16.21M | -17.3M | 0 |
| Cash from Investing | 2.6M | 2.39M | -119.24M | -4.46M | -16.78M | -2.8M | 115.22M | -47.93M | -16.06M | -44K | -8.97M | -85.92M | -2.8M | -1.06M | -1.78M | -69.2M | -6.11M | -4.06M | 1.4M |
| Capital Expenditures | -285K | -1.74M | -1.12M | -4.46M | -16.78M | -13.05M | -990K | -1.07M | -876K | -44K | -617K | -1.15M | -1.02M | -1.02M | -1.1M | -5.42M | -3.96M | -557K | -1.2M |
| CapEx % of Revenue | - | - | - | - | 67.15% | 134.08% | 5.53% | 107.54% | 10.71% | 0.01% | 0.11% | 0.22% | 0.2% | 0.2% | 0.25% | 1.32% | 1.14% | 0.17% | 0.33% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 64.11M | 118K | 0 | 0 | 0 | -86.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 110M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7.5M | -6.71M | -8.32M | 4.08M | -1.67M | 2.66M | 477K | -63.31M | -2.15M | 6.67M | 2.6M |
| Cash from Financing | 75.23M | 75.25M | 111.31M | 236K | 41.51M | 242.69M | 303K | 76.94M | 11.05M | 64.95M | 0 | 70.53M | -14.31M | -14.31M | -15.29M | 49.97M | -2.44M | -4.26M | -6.03M |
| Debt Issued (Net) | 0 | -150K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 75.31M | 75.5M | 110.92M | 386K | 43.36M | 238.13M | 460K | 76.92M | 10.82M | 64.95M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -55.68M | 0 | -34.02M | -42.9M | -33.23M | -24.86M | 0 | 0 | 0 | 0 |
| Other Financing | -89K | -104K | 389K | -150K | -1.85M | 4.56M | -157K | 30K | 221K | 0 | 0 | 70.53M | -14.31M | -14.31M | -15.29M | 49.97M | -2.44M | -4.26M | -6.03M |
| Net Change in Cash | -2.31M | -17.61M | -100.31M | -97.94M | -20.04M | 188.84M | 73.97M | 1.13M | -23.19M | 30.48M | -8.88M | 9.67M | 8.37M | 8.37M | -3.8M | -2.19M | -26.91M | 11.25M | 14.2M |
| Free Cash Flow | -80.43M | -96.98M | -93.5M | -98.18M | -61.55M | -64.1M | -42.54M | -28.95M | -19.06M | -11.6M | 7.73M | 23.91M | 24.45M | 22.71M | 12.17M | 8.61M | -19.46M | 21.95M | 14.22M |
| FCF Margin % | - | - | - | - | -246.29% | -658.77% | -237.63% | -2909.75% | -232.93% | -2.08% | 1.41% | 4.69% | 4.89% | 4.54% | 2.74% | 2.09% | -5.61% | 6.8% | 3.95% |
| FCF Growth % | 19.86% | -3.73% | 4.77% | -59.52% | 3.98% | -50.67% | -46.94% | -51.93% | -64.32% | -250.1% | -67.69% | -2.22% | 7.68% | 86.58% | 41.31% | 144.26% | -188.64% | 54.38% | - |
| FCF per Share | -7.48 | -14.07 | -17.03 | -36.50 | -23.97 | -33.13 | -92.99 | -24.96 | -10.23 | -6.88 | 4.41 | 15.31 | 16.29 | 15.13 | 8.30 | 6.03 | -14.11 | 16.07 | 10.49 |
| FCF Conversion (FCF/Net Income) | 0.88x | 0.82x | 0.79x | 0.66x | 0.64x | 0.82x | 1.13x | 0.99x | 1.96x | 0.34x | -8343.00x | 0.86x | 1.14x | 1.06x | 0.78x | 1.57x | -2.36x | 2.61x | 1.14x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 43K | 3K | 1K | 5.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ACET stock.
Adicet Bio, Inc. (ACET) generated $-95.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Adicet Bio, Inc. (ACET) reported negative free cash flow of $97.0M in 2025, indicating capital requirements exceeded cash from operations.
Adicet Bio, Inc. (ACET) spent $1.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.